The Unified Patent Court (UPC) is likely to spark years of uncertainty and may even become part of the UK’s negotiations for Brexit.
This is according to Frits Gerritzen, partner at Allen & Overy, who spoke at the Life Sciences Patent Network North America, hosted by LSIPR in Boston.
“In the short term, the UPC will probably not be as it was originally designed,” said Gerritzen.
He also noted the media attention surrounding CRISPR, adding that this demonstrates that the technology is promising.
Gerritzen went on to discuss an article he presented to a panel at the event on the potential devastating effects of off-target gene mutations that researchers had come across.
To find out more, you can watch the video below.
Frits Gerritzen, Allen & Overy, CRISPR, Life Sciences Patent Network North America, Unified Patent Court, patent